In this edition of The Motley Fool's Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the treatment of high cholesterol. From the impact of generic versions of Pfizer's Lipitor to the most exciting experimental drugs in late-stage clinical trials, cholesterol continues to be an area of focus for pharmaceutical companies and investors.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.